BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34467768)

  • 21. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma.
    Salinas-Miranda E; Healy GM; Grünwald B; Jain R; Deniffel D; O'Kane GM; Grant R; Wilson J; Knox J; Gallinger S; Fischer S; Khokha R; Haider MA
    Eur Radiol; 2022 Oct; 32(10):6712-6722. PubMed ID: 36006427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features.
    Park S; Chu LC; Hruban RH; Vogelstein B; Kinzler KW; Yuille AL; Fouladi DF; Shayesteh S; Ghandili S; Wolfgang CL; Burkhart R; He J; Fishman EK; Kawamoto S
    Diagn Interv Imaging; 2020 Sep; 101(9):555-564. PubMed ID: 32278586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
    Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
    Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma.
    Ren S; Zhao R; Zhang J; Guo K; Gu X; Duan S; Wang Z; Chen R
    Abdom Radiol (NY); 2020 May; 45(5):1524-1533. PubMed ID: 32279101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Rigiroli F; Hoye J; Lerebours R; Lafata KJ; Li C; Meyer M; Lyu P; Ding Y; Schwartz FR; Mettu NB; Zani S; Luo S; Morgan DE; Samei E; Marin D
    Radiology; 2021 Dec; 301(3):610-622. PubMed ID: 34491129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients.
    Wang K; Karalis JD; Elamir A; Bifolco A; Wachsmann M; Capretti G; Spaggiari P; Enrico S; Balasubramanian K; Fatimah N; Pontecorvi G; Nebbia M; Yopp A; Kaza R; Pedrosa I; Zeh H; Polanco P; Zerbi A; Wang J; Aguilera T; Ligorio M
    Ann Surg Oncol; 2024 Apr; 31(4):2608-2620. PubMed ID: 38151623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multidomain fusion model of radiomics and deep learning to discriminate between PDAC and AIP based on
    Wei W; Jia G; Wu Z; Wang T; Wang H; Wei K; Cheng C; Liu Z; Zuo C
    Jpn J Radiol; 2023 Apr; 41(4):417-427. PubMed ID: 36409398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma.
    Attiyeh MA; Chakraborty J; McIntyre CA; Kappagantula R; Chou Y; Askan G; Seier K; Gonen M; Basturk O; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Allen PJ; Iacobuzio-Donahue CA; Simpson AL; Do RK
    Abdom Radiol (NY); 2019 Sep; 44(9):3148-3157. PubMed ID: 31243486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involvement in Pancreatic Ductal Adenocarcinoma.
    Zhou Y; Wang J; Zhang SL; Wang H; Yan Y; Qi X; Chen S; Chen FM
    Ann Surg Oncol; 2023 Feb; 30(2):1206-1216. PubMed ID: 36264518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features and Computed Tomography Radiomics-Based Model for Predicting Pancreatic Ductal Adenocarcinoma and Focal Mass-Forming Pancreatitis.
    Ye Y; Zhang J; Song P; Qin P; Hu Y; An P; Li X; Lin Y; Wang J; Feng G
    Technol Cancer Res Treat; 2023; 22():15330338231180792. PubMed ID: 37287274
    [No Abstract]   [Full Text] [Related]  

  • 32. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis.
    Eilaghi A; Baig S; Zhang Y; Zhang J; Karanicolas P; Gallinger S; Khalvati F; Haider MA
    BMC Med Imaging; 2017 Jun; 17(1):38. PubMed ID: 28629416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images.
    Qureshi TA; Gaddam S; Wachsman AM; Wang L; Azab L; Asadpour V; Chen W; Xie Y; Wu B; Pandol SJ; Li D
    Cancer Biomark; 2022; 33(2):211-217. PubMed ID: 35213359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of residual tumor and overall survival after first-line surgery in patients with pancreatic ductal adenocarcinoma using preoperative magnetic resonance imaging findings.
    Bae JS; Kim JH; Kang HJ; Han JK
    Acta Radiol; 2022 Apr; 63(4):435-446. PubMed ID: 33682455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
    Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
    Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery.
    Dickinson SM; McIntyre CA; Schilsky JB; Harrington KA; Gerst SR; Flynn JR; Gonen M; Capanu M; Wong W; Lawrence S; Allen PJ; O'Reilly EM; Jarnagin WR; D'Angelica MI; Balachandran VP; Drebin JA; Kingham TP; Simpson AL; Do RK
    Abdom Radiol (NY); 2021 Apr; 46(4):1607-1617. PubMed ID: 32986175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?
    Marchegiani G; Andrianello S; Perri G; Secchettin E; Maggino L; Malleo G; Bassi C; Salvia R
    HPB (Oxford); 2018 May; 20(5):411-417. PubMed ID: 29191689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applying a radiomics-based strategy to preoperatively predict lymph node metastasis in the resectable pancreatic ductal adenocarcinoma.
    Liu P; Gu Q; Hu X; Tan X; Liu J; Xie A; Huang F
    J Xray Sci Technol; 2020; 28(6):1113-1121. PubMed ID: 33074215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and validation of a deep learning radiomics model with clinical-radiological characteristics for the identification of occult peritoneal metastases in patients with pancreatic ductal adenocarcinoma.
    Shi S; Lin C; Zhou J; Wei L; Chen M; Zhang J; Cao K; Fan Y; Huang B; Luo Y; Feng ST
    Int J Surg; 2024 May; 110(5):2669-2678. PubMed ID: 38445459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
    Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
    Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.